Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.88 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.88 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.88 |
| ▸ | MAPT | P10636 | 8/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.88 |
| ▸ | TSHR | P16473 | 5/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.88 |
| ▸ | MEN1 | O00255 | 4/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.88 |
| ▸ | MTOR | P42345 | 3/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.88 |
| ▸ | DRD2 | P14416 | 2/20 | 0.88 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levisoprenaline SCHEMBL250806 | 0.94 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Levisoprenaline SCHEMBL29620666 | 0.94 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL4165 | 0.94 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL3253794 | 0.94 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL4166 | 0.94 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL29519146 | 0.94 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL29386243 | 0.94 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL8508110 | 0.93 | MAPT (0.76) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL3672791 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2HSD17B10 | |
| Isoproterenol SCHEMBL1333049 | 0.92 | MAPT (0.97) | MAPTTDP1KDM4EADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4978332-A | Reduced effect on cells distant from the site | MATRIX PHARMACEUTICAL, INC. (US) | 1990-12-18 | — | — | US | claimed |
| EP-0335966-A4 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS. | MATRIX PHARMA INC (US) | 1990-02-20 | — | — | EP | claimed |
| EP-0335966-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-10-11 | — | — | EP | claimed |
| WO-1989002734-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-04-06 | — | — | WO | claimed |
| JP-63107916-A | — | — | None | — | — | JP | disclosed |
| US-20240122746-A1 | TISSUE TREATMENT METHODS | JUNIPER MEDICAL, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20230040940-A1 | TISSUE TREATMENT METHODS | JUNIPER MEDICAL, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3436190-A1 | CATECHOLAMINE-BASED CATALYST AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING METHOD | IFP Energies nouvelles (FR) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017167522-A1 | CATECHOLAMINE-BASED CATALYST AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING METHOD | IFP Energies Nouvelles (FR) | 2017-10-05 | — | — | WO | disclosed |
| US-20150328077-A1 | TISSUE TREATMENT METHODS | JUNIPER MEDICAL, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20130066309-A1 | TISSUE TREATMENT METHODS | ZELTIQ AESTHETICS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8192474-B2 | Tissue treatment methods | ZELTIQ AESTHETICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110171199-A1 | METHOD FOR REDUCING OR ELIMINATING PAIN ASSOCIATED WITH A POST-OPERATIVE WOUND | CHIU DAVID TAK WAI | 2011-07-14 | — | — | US | disclosed |
| WO-2008060423-A2 | TISSUE TREATMENT METHODS | ZELTIQ AESTHETICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080077202-A1 | Tissue Treatment Methods | JUNIPER MEDICAL, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| JP-S63107916-A | FORMULATION OF CATECHOLAMINES FOR EXTERNAL USE | NIKKEN KAGAKU KK | 1988-05-12 | — | — | JP | disclosed |
| US-4164570-A | FOR TOPICAL TREATMENT OF GLAUCOMA | CLOUGH DAVID (GB) | 1979-08-14 | — | — | US | disclosed |